Kardiotoxicita a kardiovaskulární nežádoucí účinky

Warning

This publication doesn't include Faculty of Sports Studies. It includes Faculty of Medicine. Official publication website can be found on muni.cz.
Title in English Cardiotoxicity and cardiovascular side effects
Authors

HALÁMKOVÁ Jana NOVOTNÝ Jan VYSOČANOVÁ Petra

Year of publication 2016
Type Chapter of a book
MU Faculty or unit

Faculty of Medicine

Citation
Description Cardiotoxicity is one of the serious side effects of oncology treatment, it is most often associated with anthracycline (doxorubicin, epirubicin, daunomycin), less frequently anthracenoids (mitoxantrone). Alkylating agents are cardiotoxic primarily at higher doses (cyclophosphamide, ifosfamide). Rarely cardiotoxicity was described in 5-fluorouracil, mitomycin C, cisplatin, vincristine, bleomycin and paclitaxel treatment. Cardiotoxicity is now also reported in targeted anti-cancer treatments, especially anti-HER2 drugs (trastuzumab, pertuzumab, trastuzumab emtansin, lapatinib).

You are running an old browser version. We recommend updating your browser to its latest version.

More info